Definitive Healthcare (NASDAQ:DH) Updates FY 2025 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.230-0.240 for the period, compared to the consensus EPS estimate of 0.170. The company issued revenue guidance of $239.0 million-$240.0 million, compared to the consensus revenue estimate of $238.5 million. Definitive Healthcare also updated its Q4 2025 guidance to 0.050-0.060 EPS.

Definitive Healthcare Stock Performance

Shares of DH traded down $0.07 during mid-day trading on Thursday, hitting $2.65. 249,775 shares of the company traded hands, compared to its average volume of 259,881. The stock has a market cap of $379.32 million, a price-to-earnings ratio of -1.00 and a beta of 1.61. The stock has a 50-day moving average price of $3.49 and a two-hundred day moving average price of $3.57. Definitive Healthcare has a 1 year low of $2.15 and a 1 year high of $5.68. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.65 and a current ratio of 1.65.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, November 6th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $60.05 million during the quarter, compared to the consensus estimate of $59.51 million. Definitive Healthcare had a negative net margin of 124.43% and a positive return on equity of 3.94%. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS. Q4 2025 guidance at 0.050-0.060 EPS. Equities analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Robert W. Baird set a $4.00 price objective on Definitive Healthcare in a research report on Friday, August 8th. Stifel Nicolaus boosted their price target on Definitive Healthcare from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $4.28.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DH. Raymond James Financial Inc. bought a new stake in Definitive Healthcare during the 2nd quarter worth approximately $32,000. Creative Planning raised its position in shares of Definitive Healthcare by 41.7% during the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after purchasing an additional 8,428 shares during the period. Invesco Ltd. raised its position in shares of Definitive Healthcare by 17.8% during the 2nd quarter. Invesco Ltd. now owns 72,900 shares of the company’s stock valued at $284,000 after purchasing an additional 11,029 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Definitive Healthcare by 357.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,233 shares of the company’s stock valued at $67,000 after buying an additional 13,466 shares in the last quarter. Finally, Bayesian Capital Management LP bought a new position in Definitive Healthcare in the 2nd quarter worth $55,000. 98.67% of the stock is owned by hedge funds and other institutional investors.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.